Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.46) by 15.22 percent. This is a 165 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $6.47 million which missed the analyst consensus estimate of $13.56 million by 52.25 percent. This is a 66.83 percent decrease over sales of $19.52 million the same period last year.